Your browser doesn't support javascript.
loading
Exposure to potentially inappropriate medications in Brazilian elderly outpatients with metabolic diseases
Martins, Vanessa dos Santos; Mori, Ana Luiza Pereira Moreira; Dorea, Egidio Lima; Pinto, Gelba Almeida; Hirata, Mario Hiroyuki; Hirata, Felipe Dominguez Crespo; Hirata, Rosario Dominguez Crespo.
  • Martins, Vanessa dos Santos; University of Sao Paulo. School of Pharmaceutical Sciences. Sao Paulo. BR
  • Mori, Ana Luiza Pereira Moreira; University of Sao Paulo. University Hospital. Sao Paulo. BR
  • Dorea, Egidio Lima; University of Sao Paulo. University Hospital. Sao Paulo. BR
  • Pinto, Gelba Almeida; University of Sao Paulo. University Hospital. Sao Paulo. BR
  • Hirata, Mario Hiroyuki; University of Sao Paulo. School of Pharmaceutical Sciences. Sao Paulo. BR
  • Hirata, Felipe Dominguez Crespo; State Center for Technological Education Paula Souza. School of Technology. São Paulo. BR
  • Hirata, Rosario Dominguez Crespo; University of Sao Paulo. School of Pharmaceutical Sciences. Sao Paulo. BR
Braz. j. pharm. sci ; 52(4): 699-707, Oct.-Dec. 2016. tab, graf
Artigo em Inglês | LILACS | ID: biblio-951879
ABSTRACT
ABSTRACT Management of pharmacotherapy in elderly with metabolic diseases is challenging and potentially inappropriate medications (PIMs) are risk factors for drug interactions and adverse events. The exposure to PIMs in elderly outpatients with metabolic diseases and its relationship with polypharmacy and other variables was investigated. PIMs prescribed to 207 elderly patients (aged 60 to 96 years) with metabolic diseases who attended a University Hospital of Sao Paulo city, Brazil, from April/2010 to January/2011, were evaluated. PIMs were detected using both 2003 Beers and 2008 STOPP criteria. The association between PIMs and age, gender and polypharmacy was also examined. 2008 STOPP criteria detected more PIMs (44.4 %) than 2003 Beers criteria (16.0%, p<0.001). Beers detected mainly PIMs antihypertensive (clonidine, 20.0%; doxazosin, 10.0%) and antidepressant (fluoxetine, 15.0%; amitriptyline, 10.0%) PIMs. Medicines used for cardiovascular (aspirin, 53.7%) and endocrine system (glibenclamide, 21.3%) were PIMs more frequently detected by 2008 STOPP. Unlike age and gender, polypharmacy increased the risk of PIMs by both 2003 Beers (OR: 4.0, CI95%: 1.2-13.8, p<0.031) and 2008 STOPP (OR: 6.8, CI95%: 3.0-15.3, p<0.001). Beers and STOPP criteria are important tools to evaluate the exposure to PIMs, which is strongly associated with polypharmacy in elderly outpatients with metabolic diseases.
Assuntos


Texto completo: DisponíveL Índice: LILACS (Américas) Assunto principal: Idoso / Fatores de Risco / Instituições de Assistência Ambulatorial / Doenças Metabólicas Tipo de estudo: Estudo de etiologia / Fatores de risco Limite: Idoso / Aged80 / Feminino / Humanos / Masculino País/Região como assunto: América do Sul / Brasil Idioma: Inglês Revista: Braz. j. pharm. sci Ano de publicação: 2016 Tipo de documento: Artigo País de afiliação: Brasil Instituição/País de afiliação: State Center for Technological Education Paula Souza/BR / University of Sao Paulo/BR

Similares

MEDLINE

...
LILACS

LIS


Texto completo: DisponíveL Índice: LILACS (Américas) Assunto principal: Idoso / Fatores de Risco / Instituições de Assistência Ambulatorial / Doenças Metabólicas Tipo de estudo: Estudo de etiologia / Fatores de risco Limite: Idoso / Aged80 / Feminino / Humanos / Masculino País/Região como assunto: América do Sul / Brasil Idioma: Inglês Revista: Braz. j. pharm. sci Ano de publicação: 2016 Tipo de documento: Artigo País de afiliação: Brasil Instituição/País de afiliação: State Center for Technological Education Paula Souza/BR / University of Sao Paulo/BR